Siolta Therapeutics Raises $12 Million in Series C Financing for Clinical Development
- 3.13.2024
WilmerHale represented Siolta Therapeutics, Inc., a biotech company developing live biotherapeutics that target the core drivers of disease, in its $12 million Series C financing. The final closing of the round occurred on February 23, 2024. The financing was led by Khosla Ventures and SymBiosis. The funds raised in this round will support the further clinical development of Siolta’s lead product, STMC-103H, a defined-consortia Live Biotherapeutic Product (LBP) focused on preventing the onset of atopic diseases in newborns.
The team representing Siolta Therapeutics consisted of Daniel Zimmermann, Frances Mosley, Aric Jain and Amanda Rossetta.
